Russia's Sputnik V vaccine has been found in an interim analysis to be 91.6 percent effective against symptomatic COVID-19.
The interim phase 3 trial analysis for Russia's vaccine was confirmed in a peer review from the medical journal The Lancet, which showed that it provided full protection against moderate and severe COVID-19 cases, the Financial Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
US foodies brace for tariff warUnder The Radar Shoppers stocking up on imported olive oil, maple syrup and European wine as price hikes loom
-
How Canadian tariffs could impact tourism to the USIn the Spotlight Canadians represent the largest group of foreign visitors to the United States. But they may soon stop visiting.
-
Entitlements: DOGE goes after Social SecurityFeature Elon Musk is pushing false claims about Social Security fraud
-
Texas outbreak brings 1st US measles death since 2015Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
-
Mystery illness spreading in Congo rapidly kills dozensSpeed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
-
Ozempic can curb alcohol cravings, study findsSpeed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
